Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Michael Untch,Richard D. Gelber,Christian Jackisch,Marion Procter,José Baselga,Richard Bell,David Cameron,M. Bari,Ian E. Smith,Brian Leyland-Jones,E. de Azambuja,P. Wermuth,Rustem Khasanov,F. Feng-yi,C. Constantin,Jose I. Mayordomo,C.-H. Su,Shu-Yan Yu,A. Lluch,Elżbieta Senkus-Konefka,C. G. A. Price,F. Haslbauer,T. Suarez Sahui,Vichien Srimuninnimit,Marco Colleoni,Alan S. Coates,Martine Piccart-Gebhart,Aron Goldhirsch +27 more
TLDR
Adjuvant trastuzumab therapy reduces the risk of relapse similarly across subgroups defined by nodal status and steroid hormone receptor status, even those at relatively low risk for relapse.About:
This article is published in Annals of Oncology.The article was published on 2008-06-01 and is currently open access. It has received 187 citations till now. The article focuses on the topics: Trastuzumab & Adjuvant therapy.read more
Citations
More filters
Journal ArticleDOI
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz,Michael Untch,Jens-Uwe Blohmer,SD Costa,Holger Eidtmann,Peter A. Fasching,Bernd Gerber,Wolfgang Eiermann,Jörn Hilfrich,Jens Huober,Christian Jackisch,Manfred Kaufmann,Gottfried E. Konecny,Carsten Denkert,Valentina Nekljudova,Keyur Mehta,Sibylle Loibl +16 more
TL;DR: The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain this paper, however, it is known that pCR is associated with long-term outcome of 6,377 patients with primary breast cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Bella Kaufman,John R. Mackey,Michael R. Clemens,P.P. Bapsy,Ashok K. Vaid,Andrew M Wardley,Sergei Tjulandin,Michaela Jahn,Michaela Lehle,A. Feyereislova,Cedric Revil,Alison Jones +11 more
TL;DR: Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor-copositive MBC compared with anast rozole alone, although adverse events and serious adverse events were more frequent with the combination.
Journal ArticleDOI
Clinical implications of the intrinsic molecular subtypes of breast cancer.
Aleix Prat,Aleix Prat,Estela Pineda,Barbara Adamo,Barbara Adamo,Patricia Galván,Aranzazu Fernandez,Aranzazu Fernandez,Lydia Gaba,Lydia Gaba,Marc Díez,Marc Díez,Margarita Viladot,Margarita Viladot,Ana Arance,Ana Arance,Montserrat Muñoz,Montserrat Muñoz +17 more
TL;DR: Data suggests that intrinsic molecular profiling provides clinically relevant information beyond current pathology-based classifications within triple-negative breast cancer (TNBC) and within hormone receptor-positive and HER2-negative early breast cancer.
Journal ArticleDOI
Trastuzumab containing regimens for early breast cancer
Lorenzo Moja,Ludovica Tagliabue,Sara Balduzzi,Elena Parmelli,Vanna Pistotti,Valentina Guarneri,Roberto D'Amico +6 more
TL;DR: Trastuzumab significantly improves OS and DFS in HER2-positive women with early and locally advanced breast cancer, although it also significantly increases the risk of CHF and LVEF decline.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal ArticleDOI
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian E. Smith,Marion Procter,Richard D. Gelber,Sebastien Guillaume,A. Feyereislova,Mitch Dowsett,Aron Goldhirsch,Michael Untch,Gabriella Mariani,José Baselga,Manfred Kaufmann,David Cameron,Richard Bell,Jonas Bergh,Robert E. Coleman,Andrew M Wardley,Nadia Harbeck,Roberto Ivan Lopez,Peter Mallmann,Karen A. Gelmon,Nicholas Wilcken,Erik Wist,Pedro Sánchez Rovira,Martine Piccart-Gebhart +23 more
TL;DR: The results show that 1 year of treatment with trastuzumab after adjuvant chemotherapy has a significant overall survival benefit after a median follow-up of 2 years, and the emergence of this benefit after only 2 years reinforces the importance of trastizumab in the treatment of women with HER2-positive early breast cancer.
Journal ArticleDOI
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu,Pirkko-Liisa Kellokumpu-Lehtinen,Petri Bono,Tuomo Alanko,Vesa Kataja,Raija Asola,Tapio Utriainen,R. Kokko,Akseli Hemminki,Maija Tarkkanen,Taina Turpeenniemi-Hujanen,Sirkku Jyrkkiö,Martti Flander,Leena Helle,Seija Ingalsuo,Kaisu Johansson,Anna-Stina Jääskeläinen,Marjo Pajunen,Mervi Rauhala,Jaana Kaleva-Kerola,T. Salminen,M. Leinonen,Inkeri Elomaa,Jorma Isola +23 more
TL;DR: A short course of trastuzumab administered concomitantly with docetaxel or vinorelbine is effective in women with breast cancer who have an amplified HER2/neu gene.
Related Papers (5)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian E. Smith,Marion Procter,Richard D. Gelber,Sebastien Guillaume,A. Feyereislova,Mitch Dowsett,Aron Goldhirsch,Michael Untch,Gabriella Mariani,José Baselga,Manfred Kaufmann,David Cameron,Richard Bell,Jonas Bergh,Robert E. Coleman,Andrew M Wardley,Nadia Harbeck,Roberto Ivan Lopez,Peter Mallmann,Karen A. Gelmon,Nicholas Wilcken,Erik Wist,Pedro Sánchez Rovira,Martine Piccart-Gebhart +23 more